{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:52:10Z","timestamp":1790070730884,"version":"4.0.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.vaccine.2019.09.030","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T18:08:32Z","timestamp":1569348512000},"page":"6824-6831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs"],"prefix":"10.1016","volume":"37","author":[{"given":"Junki","family":"Maruyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Mateer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Sattler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Seregin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya","family":"Bukreyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Balint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth S.","family":"Gabitzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slobodan","family":"Paessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.09.030_b0005","unstructured":"Buchmeier MJ, de la Torre J-C, Peters CJ. Arenaviridae: The Viruses and Their Replication. In: Knipe DM, Howley PM, editors. Fields Virology: Lippincott Williams & Wilkins; 2006."},{"key":"10.1016\/j.vaccine.2019.09.030_b0010","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fpubh.2018.00232","article-title":"Lassa fever 2016 outbreak in Plateau State, Nigeria-The changing epidemiology and clinical presentation","volume":"6","author":"Shehu","year":"2018","journal-title":"Front Public Heal"},{"key":"10.1016\/j.vaccine.2019.09.030_b0015","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2105\/AJPH.2017.304186","article-title":"Mortality among confirmed lassa fever cases during the 2015\u20132016 outbreak in Nigeria","volume":"108","author":"Buba","year":"2018","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2019.09.030_b0020","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S1473-3099(18)30116-6","article-title":"Predicting outcome and improving treatment for Lassa fever","volume":"18","author":"Geisbert","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.09.030_b0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002748","article-title":"Lassa fever in post-conflict Sierra Leone","volume":"8","author":"Shaffer","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.09.030_b0030","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.3390\/v4102031","article-title":"Pathogenesis of Lassa Fever","volume":"4","author":"Yun","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2019.09.030_b0035","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/bmj.327.7426.1271","article-title":"Lassa fever: epidemiology, clinical features, and social consequences","volume":"327","author":"Richmond","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2019.09.030_b0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa Fever","volume":"314","author":"McCormick","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.09.030_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006187","article-title":"Lassa fever\u2013induced sensorineural hearing loss: A neglected public health and social burden","volume":"12","author":"Mateer","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.09.030_b0050","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/trstmh\/trv047","article-title":"Mapping the zoonotic niche of Lassa fever in Africa","volume":"109","author":"Mylne","year":"2015","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2019.09.030_b0055","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.3390\/v4102162","article-title":"Envelope Glycoprotein of Arenaviruses","volume":"4","author":"Burri","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2019.09.030_b0060","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1128\/JVI.00024-12","article-title":"Molecular characterization of the processing of arenavirus envelope glycoprotein precursors by subtilisin kexin isozyme-1\/site-1 protease","volume":"86","author":"Burri","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.09.030_b0065","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.chom.2015.11.005","article-title":"Molecular basis for antibody-mediated neutralization of New World hemorrhagic fever mammarenaviruses","volume":"18","author":"Mahmutovic","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2019.09.030_b0070","doi-asserted-by":"crossref","first-page":"11544","DOI":"10.1038\/ncomms11544","article-title":"Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits","volume":"7","author":"Robinson","year":"2016","journal-title":"Nat Commun"},{"issue":"6341","key":"10.1016\/j.vaccine.2019.09.030_b0075","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1126\/science.aam7260","article-title":"Structural basis for antibody-mediated neutralization of Lassa virus","volume":"356","author":"Hastie","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2019.09.030_b0080","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nri.2016.138","article-title":"Immunobiology of Ebola and Lassa virus infections","volume":"17","author":"Prescott","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2019.09.030_b0085","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.3390\/v4112766","article-title":"Immune responses and Lassa virus infection","volume":"4","author":"Russier","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2019.09.030_b0090","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.4049\/jimmunol.172.5.2861","article-title":"Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells","volume":"172","author":"Baize","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.09.030_b0095","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1128\/JVI.01948-08","article-title":"Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys","volume":"83","author":"Baize","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.09.030_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000836","article-title":"T Cell-dependence of lassa fever pathogenesis","volume":"6","author":"Flatz","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2019.09.030_b0105","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.virol.2003.12.013","article-title":"Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones","volume":"321","author":"ter Meulen","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.09.030_b0110","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1128\/JVI.74.5.2186-2192.2000","article-title":"Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein","volume":"74","author":"ter Meulen","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.09.030_b0115","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s004300100061","article-title":"Antibodies to Lassa virus Z protein and nucleoprotein co-occur in human sera from Lassa fever endemic regions","volume":"189","author":"G\u00fcnther","year":"2001","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2019.09.030_b0120","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00262-015-1706-4","article-title":"Extended evaluation of a phase 1\/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer","volume":"64","author":"Balint","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2019.09.030_b0125","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/cgt.2009.17","article-title":"Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity","volume":"16","author":"Osada","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.vaccine.2019.09.030_b0130","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.1016\/j.vaccine.2009.06.028","article-title":"Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity","volume":"27","author":"Gabitzsch","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.030_b0135","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1016\/j.vaccine.2011.08.038","article-title":"Induction and comparison of SIV immunity in Ad5 na\u00efve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine","volume":"29","author":"Gabitzsch","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.030_b0140","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00262-010-0847-8","article-title":"Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA","volume":"59","author":"Gabitzsch","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2019.09.030_b0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.imlet.2008.11.003","article-title":"A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses","volume":"122","author":"Gabitzsch","year":"2009","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2019.09.030_b0150","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00262-013-1400-3","article-title":"Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients","volume":"62","author":"Morse","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2019.09.030_b0155","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/COH.0000000000000090","article-title":"HIV epidemic among key populations in west Africa","volume":"9","author":"Djomand","year":"2014","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.vaccine.2019.09.030_b0160","doi-asserted-by":"crossref","first-page":"F32","DOI":"10.1016\/j.vaccine.2012.07.092","article-title":"The burden of human papillomavirus infections and related diseases in sub-Saharan Africa","volume":"31","author":"De Vuyst","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.030_b0165","doi-asserted-by":"crossref","first-page":"e0188128","DOI":"10.1371\/journal.pone.0188128","article-title":"A qualitative exploration of malaria operational research situation in Nigeria","volume":"12","author":"Ajayi","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.09.030_b0170","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12916-016-0704-5","article-title":"The emerging threat of pre-extensively drug-resistant tuberculosis in West Africa: preparing for large-scale tuberculosis research and drug resistance surveillance","volume":"14","author":"Gehre","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2019.09.030_b0175","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1016\/j.vaccine.2012.09.058","article-title":"Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform","volume":"30","author":"Gabitzsch","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.030_b0180","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1128\/JVI.02948-15","article-title":"Animal model of sensorineural hearing loss associated with lassa virus infection","volume":"90","author":"Yun","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.09.030_b0185","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00428-19","article-title":"Lethal infection of Lassa virus isolated from a human clinical sample in outbred guinea pigs without adaption","author":"Maruyama","year":"2019","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2019.09.030_b0190","doi-asserted-by":"crossref","first-page":"7020","DOI":"10.1016\/j.vaccine.2011.07.073","article-title":"Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine","volume":"29","author":"Jones","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.030_b0195","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/cgt.2010.82","article-title":"An Ad5[E1-, E2b-]-HER2\/neu vector induces immune responses and inhibits HER2\/neu expressing tumor progression in Ad5 immune mice","volume":"18","author":"Gabitzsch","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.vaccine.2019.09.030_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcimb.2017.00020","article-title":"Absence of an N-linked glycosylation motif in the glycoprotein of the live-attenuated argentine hemorrhagic fever vaccine, Candid #1, results in its improper processing, and reduced surface expression","volume":"7","author":"Manning","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2019.09.030_b0205","doi-asserted-by":"crossref","first-page":"e0004969","DOI":"10.1371\/journal.pntd.0004969","article-title":"The Ectodomain of glycoprotein from the candid#1 vaccine strain of junin virus rendered machupo virus partially attenuated in mice lacking IFN-\u03b1\u03b2\/\u03b3 receptor","volume":"10","author":"Koma","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.09.030_b0210","doi-asserted-by":"crossref","first-page":"10908","DOI":"10.1128\/JVI.01433-13","article-title":"Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus","volume":"87","author":"Yun","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.09.030_b0215","doi-asserted-by":"crossref","first-page":"31344","DOI":"10.18632\/oncotarget.5181","article-title":"The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic","volume":"6","author":"Gabitzsch","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.vaccine.2019.09.030_b0220","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever","volume":"9","author":"Abreu-Mota","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2019.09.030_b0225","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/infdis\/jix201","article-title":"A case of human lassa virus infection with robust acute T-Cell activation and long-term virus-specific T-cell responses","volume":"215","author":"McElroy","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.09.030_b0230","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-018-0049-5","article-title":"Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development","volume":"3","author":"Hallam","year":"2018","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.vaccine.2019.09.030_b0235","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.2147\/DDDT.S147276","article-title":"Current research for a vaccine against Lassa hemorrhagic fever virus","volume":"12","author":"Warner","year":"2018","journal-title":"Drug Des Devel Ther"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19312307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19312307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:35:53Z","timestamp":1759401353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19312307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":47,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0264410X19312307"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.030","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}